Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.

Ringe JD, Farahmand P, Schacht E.

Rheumatol Int. 2013 Mar;33(3):637-43. doi: 10.1007/s00296-012-2429-x. Epub 2012 Apr 8.

PMID:
22527138
2.

Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.

Ringe JD, Faber H, Fahramand P, Schacht E.

J Rheumatol Suppl. 2005 Sep;76:33-40.

PMID:
16142849
4.

Potential of alfacalcidol for reducing increased risk of falls and fractures.

Ringe JD, Schacht E.

Rheumatol Int. 2009 Aug;29(10):1177-85. doi: 10.1007/s00296-008-0835-x. Epub 2009 Jan 22.

PMID:
19159932
5.

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.

Ringe JD, Farahmand P, Faber H, Dorst A.

Rheumatol Int. 2009 Jan;29(3):311-5. doi: 10.1007/s00296-008-0689-2. Epub 2008 Sep 2.

PMID:
18762944
6.

Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.

Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW.

Rheumatol Int. 2004 Mar;24(2):63-70. Epub 2003 Sep 25.

PMID:
14513268
7.

Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.

Reginster JY, Lecart MP, Richy F.

J Rheumatol Suppl. 2005 Sep;76:21-5.

PMID:
16142847
8.

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.

Ringe JD, Faber H, Farahmand P, Dorst A.

Rheumatol Int. 2006 Mar;26(5):427-31. Epub 2005 Jul 7.

PMID:
16001181
9.

Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.

Ringe JD, Schacht E, Dukas L, Mazor Z.

Arzneimittelforschung. 2011;61(2):104-11. doi: 10.1055/s-0031-1296175.

PMID:
21428245
10.

[Therapy of glucocorticoid-induced osteoporosis with alfacalcidol/calcium and vitamin D/calcium].

Ringe JD, Cöster A, Meng T, Schacht E, Umbach R.

Z Rheumatol. 2000 Jun;59(3):176-82. German.

PMID:
10929446
11.

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.

Ringe JD, Schacht E.

Rheumatol Int. 2007 Dec;28(2):103-11. Epub 2007 Aug 1. Review.

PMID:
17668216
13.

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.

Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis) research group.

Curr Med Res Opin. 2011 Jun;27(6):1273-84. doi: 10.1185/03007995.2011.580341. Epub 2011 May 10.

PMID:
21554143
14.

Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass.

Schacht E, Ringe JD.

Rheumatol Int. 2012 Jan;32(1):207-15. doi: 10.1007/s00296-010-1607-y. Epub 2010 Sep 9.

PMID:
20827552
15.

Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.

Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.

J Bone Miner Metab. 2009;27(2):168-74. doi: 10.1007/s00774-008-0024-8. Epub 2009 Jan 28.

PMID:
19183836
16.

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.

Yonsei Med J. 2009 Aug 31;50(4):474-81. doi: 10.3349/ymj.2009.50.4.474. Epub 2009 Aug 19.

17.

Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.

Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.

Epilepsia. 2013 Nov;54(11):1997-2004. doi: 10.1111/epi.12351. Epub 2013 Sep 6.

18.

Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol.

Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R, Yamamoto K, Sugioka Y, Inoue A, Takaoka K, Yamamoto I, Hoshino Y, Kawaguchi H.

J Bone Miner Metab. 2007;25(2):130-7. Epub 2007 Feb 26.

PMID:
17323183
19.

The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.

Schacht E, Richy F, Reginster JY.

J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84. Review.

20.

Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.

Ringe JD, Cöster A, Meng T, Schacht E, Umbach R.

Calcif Tissue Int. 1999 Oct;65(4):337-40.

PMID:
10485988

Supplemental Content

Support Center